A lack of evidence is behind the NHS' decision to withhold a breakthrough prostate cancer drug from patients who have already been treated using another new generation drug, Nice said.
A spokeswoman for Nice said the committee were unable to "draw any conclusions" about what would happen if "milestone" enzalutamide was used by prostate cancer sufferers who had also taken abiraterone.
In the trial data provided by the manufacturer of enzalutamide none of the patients had received previous treatment with abiraterone, therefore the committee was not able to draw any conclusions about the effectiveness of enzalutamide after previous abiraterone treatment, and this is reflected in the recommendations.
We would welcome any additional data the manufacturer of enzalutamide can provide.
More top news
A new law which allows councils to ban activities in public spaces is leading to "bizarre new criminal offences", campaigners claim.
The Serious Fraud Office has been fined £180k after confidential documents from a high-profile investigation were sent to the wrong person.
British hopes for a sunny Easter break have been dealt a blow with forecasters warning of a week of wind, rain and even snow.